![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR
ARRAY BIOPHARMA BEGINS TRIAL OF MEK INHIBITOR
May 12, 2006
Array BioPharma has announced the initiation of a Phase I clinical trial for its proprietary small molecule, ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease.
ARRY-438162 will be evaluated in dose escalation studies in normal, healthy volunteers. Array scientists demonstrated ARRY-438162 to be potent, selective, well-tolerated and efficacious in preclinical models of human inflammatory diseases.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct